Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 55Endometrial Neoplasms 7Ovarian Neoplasms 5Neoplasm Metastasis 5Polycystic Ovary Syndrome 4Neoplasms 4Advanced Breast Cancer 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Carcinoma, Intraductal, Noninfiltrating 3Recurrence 2Neoplasms by Site 2Infertility 2HR+/HER2- Breast Cancer 2Estrogen Receptor-positive Breast Cancer 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Breast Diseases 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sexual Dysfunctions, Psychological 1Pathologic Complete Response 1Pancreatic Neoplasms 1Low-Grade Serous Ovarian Cancer 1Low Grade Serous Ovarian Carcinoma 1Low Grade Serous Ovarian Cancer 1Locoregional Recurrence 1Leiomyoma 1

Interventions

talimogene laherparepvec 1exemestane 1Tamoxifen 1Surgical Procedures, Operative 1Specimen Handling 1Paclitaxel 1Mastectomy, Segmental 1Letrozole 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ductal × Letrozole × 90 days × Clear all
NCT05183828 2026-06-04

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

University of Washington

Phase 4 Terminated
62 enrolled

Carcinoma, Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡